Carlo Carnaghi

TL;DR: Everolimus is the first targeted agent to show robust anti-tumour activity with acceptable tolerability across a broad range of neuroendocrine tumours, including those arising from the pancreas, lung, and gastrointestinal tract.

TL;DR: In a larger and more homogeneous series than in previous studies, exploratory data suggest that mCRC patients with tumors distinguishable by FISH analysis of EGFR as homogenously disomic or with low chromosome 7 polysomy have a reduced likelihood of response to panitumumab.

TL;DR: Overall survival of patients attaining a disease free status (clinical complete responders+radically resected) was significantly higher than that of patients with partial response or no response (P<0.002), androgen secretion was associated with long survival, while glucocorticoid secretion wasassociated with poor prognosis both in univariate and multivariate analysis.

TL;DR: Tumor MSI is a stage-dependent predictor of survival in patients with colorectal cancer, and the decreased likelihood of metastases in Patients with MSI cancer is associated with specific genetic and epigenetic changes of the primary tumor.

TL;DR: Assessment of AFP response may be considered as an alternative to RECIST to capture sorafenib activity in HCC and improve prognostic usefulness of imaging-based Response Evaluation Criteria in Solid Tumors.